Surgery with curative intent in patients (pts) treated with first-line chemotherapy (CT) plus bevacizumab (BEV) for metastatic colorectal cancer (mCRC): First BEAT and NO16966

被引：13
|
作者：
Cassidy, J.
Cunningham, D.
Berry, S. R.
Rivera, F.
Clarke, S. J.
Kretzschmar, A.
Diaz-Rubio, E.
机构：
[1] Canc Res UK, Glasgow, Lanark, Scotland
[2] Royal Marsden Hosp, Sutton, Surrey, England
[3] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada
[4] Hosp Marques de Valdecilla, Santander, Spain
[5] Univ Sydney, Sydney, NSW 2006, Australia
[6] Sydney Canc Ctr, Sydney, NSW, Australia
[7] HELIOS Klin, Berlin, Germany
[8] Hosp Clin San Carlos, Madrid, Spain
[9] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
[10] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.4022
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4022
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial
    A Okines
    O del Puerto
    D Cunningham
    I Chau
    E Van Cutsem
    L Saltz
    J Cassidy
    [J]. British Journal of Cancer, 2009, 101 : 1033 - 1038
  • [2] Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial
    Okines, A.
    Del Puerto, O.
    Cunningham, D.
    Chau, I.
    Van Cutsem, E.
    Saltz, L.
    Cassidy, J.
    [J]. BRITISH JOURNAL OF CANCER, 2009, 101 (07) : 1033 - 1038
  • [3] Efficacy and safety of surgery with curative intent in patients treated with first-line Bevacizumab plus chemotherapy for metastatic colorectal cancer: First beat
    Kretzschmar, A.
    Cunningham, D.
    Berry, S.
    Rivera, F.
    Di Bartolomeo, M.
    Mazier, M.
    Van Cutsem, E.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : I25 - I25
  • [4] EFFECTIVENESS AND SAFETY OF FIRST-LINE BEVACIZUMAB PLUS FOLFIRI IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Pinto, Ana Catarina
    Teixeira, Margarida
    Bonito, Nuno
    Jacinto, Paula
    Ribeiro, Joao
    Gervasio, Helena
    [J]. ANNALS OF ONCOLOGY, 2011, 22 : v98 - v98
  • [5] BEVACIZUMAB (BEV) plus CHEMOTHERAPY (CT) BEYOND FIRST PROGRESSION IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) PREVIOUSLY TREATED WITH FIRST-LINE BEV plus CT (ML18147): EFFICACY AND SAFETY ANALYSES BY OXALIPLATIN VS IRINOTECAN-BASED CT
    Osterlund, P.
    Alonso-Orduna, V.
    Schlichting, C.
    Andre, T.
    Sastre, J.
    Greil, R.
    Kubicka, S.
    Reyes-Rivera, I.
    McCall, B.
    Van Cutsem, E. J. D.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 195 - 195
  • [6] SAFETY AND EFFICACY OF BEVACIZUMAB PLUS STANDARD FIRST-LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER: FIRST BEAT
    Van Cutsem, E.
    Berry, S.
    Michael, M.
    Kretzschmar, A.
    Rivera, F.
    DiBartolomeo, M.
    Mazier, M.
    Andre, N.
    Cunningham, D.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 125 - 125
  • [7] FDG-PET/CT (PET) in the early prediction of benefit from first-line chemotherapy plus bevacizumab (bev) in metastatic colorectal cancer (mCRC).
    Salvatore, Lisa
    Loupakis, Fotios
    Cremolini, Chiara
    Schirripa, Marta
    Antoniotti, Carlotta
    Marmorino, Federica
    Zoratto, Federica
    Bergamo, Francesca
    Brunetti, Isa Maura
    Pfanner, Elisabetta
    Masi, Gianluca
    Genovesi, Dario
    Filidei, Elena
    Giorgetti, Assuero
    Falcone, Alfredo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Bevacizumab (BEV) continued beyond first progression in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with BEV plus chemotherapy (CT): Biomarker findings from ML18147.
    Kubicka, Stefan
    Von Moos, Roger
    Greil, Richard
    Sastre, Javier
    Osterlund, Pia J.
    Arnold, Dirk
    Andre, Thierry
    Van Cutsem, Eric
    Mueller, Thomas
    Reyes-Rivera, Irmarie
    Bennouna, Jaafar
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [9] SINGLE INSTITUTION RESULTS OF FIRST-LINE TREATMENT WITH BEVACIZUMAB PLUS CHEMOTHERAPY IN METASTATIC COLORECTAL CANCER (MCRC)
    Barkmanova, Jaroslava
    Petruzelka, Lubos
    Sedlackova, Eva
    Vocka, Michal
    Hejduk, Karel
    Bortlicek, Zbynek
    [J]. ANNALS OF ONCOLOGY, 2014, 25
  • [10] Safety analysis of first-line bevacizumab plus chemotherapy in patients with metastatic colorectal cancer (mCRC) participating in a US registry
    Kozloff, M.
    Cohn, A.
    Christiansen, N.
    Flynn, P.
    Kabbinavar, F.
    Robles, R.
    Ulcickas-Yood, M.
    Sarkar, S.
    Hambleton, J.
    Grothey, A.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 173 - 173
12345